Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAPDH | P04406 | 1/20 | 0.37 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29090809 | 0.85 | MAPT (0.52) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL8987849 | 0.83 | LGALS9 (0.46) | MAPTPOLBABCB1SLC43A1 | |
| SCHEMBL11075412 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL27514476 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL7746169 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL308251 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL308252 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL28604390 | 0.80 | MAPT (0.57) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL6222324 | 0.80 | MAPT (0.50) | MAPTALDH1A1POLBMEN1USP2 | |
| SCHEMBL23898235 | 0.78 | MAPT (0.51) | MAPTALDH1A1POLBMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900298-B2 | Process for producing nucleic acid derivative | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030153745-A1 | Process for producing nucleic acid derivative | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1334978-A1 | Process for preparing nucleic acid derivative | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153745-A1 | Process for producing nucleic acid derivative | RNGTT, POLRMT, NT5C3B | MAPT 3046/4885ALDH1A1 2074/4885POLB 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.